Key result
App-based biofeedback reduces monthly migraine days by ~1 day versus waitlist control.
Why the study?
The study was conducted to evaluate the efficacy and safety of a fully self-administered, app-based biofeedback intervention for the prevention of episodic migraine.
Does app-based self-administered biofeedback reduce monthly migraine days in adults with episodic migraine?
RCT (n=279)
Open-label
randomized
Yes
Does app-based self-administered biofeedback reduce monthly migraine days in adults with episodic migraine?
App-based self-administered biofeedback significantly reduces migraine frequency and improves quality of life in adults with episodic migraine.
Answers are grounded in this paper and cite their sources.
Opens a scalable nonpharmacologic option for episodic migraine; provides first RCT evidence for fully self-administered app biofeedback.
Aim To evaluate the efficacy and safety of a fully self-administered, app-based biofeedback intervention for the prevention of episodic migraine Methods This open-label, randomized, waitlist-controlled multicenter trial included adults with episodic migraine assigned to 12 weeks of daily biofeedback or a waitlist control. The primary outcome was change in monthly migraine days (MMDs) from baseline to weeks 9–12. Secondary outcomes included migraine intensity, acute medication use, and migraine-specific quality of life (MSQ v2.1). Statistical analyses were performed according to the intention-to-treat principle by a statistician masked to treatment assignment. Results Of 1113 individuals screened, 279 participants (mean [SD] age, 41 [10] years; 92% women) were randomized to the intervention (n = 140) or waitlist control (n = 139). Baseline MMDs were 4.8 (2.4) and 4.6 (2.3) in the intervention and control groups, respectively. During weeks 9–12, the estimated reduction in MMDs was 0.9 days (95% CI, −1.4 to −0.5) in the intervention group and 0.0 days (95% CI, −0.5 to 0.4) in the control group (between-group difference, 0.9 days; 95% CI, 0.3 to 1.5; P = 0.002). Participants receiving biofeedback also showed greater improvements in MSQ v2.1 total scores (mean difference, 5.3 points; 95% CI, 2.1 to 8.6; P = 0.001). Nine device-related adverse events occurred, all with mild severity. Conclusion App-based self-administered biofeedback was associated with a statistically significant reduction in migraine frequency and improved quality of life, with a favorable safety profile.
No takes yet. Share an insight, caveat, or question.
Poole et al. (2026) conducted an RCT in episodic migraine (n=279). App-based self-administered biofeedback vs. waitlist control was evaluated on change in monthly migraine days (MMDs) from baseline to weeks 9–12 (MD 0.9, 95% CI 0.3 to 1.5, p=0.002). App-based self-administered biofeedback reduced monthly migraine days compared to waitlist control.
Synapse has enriched 10 related papers. Consider them for comparative context: